Search
Beam Therapeutics Inc
BEAMAdd to Watchlist
34.140USD
+1.660+5.11%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
3.51BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Beam Therapeutics Inc is 8.74, ranking 71 out of 389 in the Biotechnology & Medical Research industry. The average price target is 42.00, with a high of 80.00 and a low of 21.00.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
50.021
Target Price
+46.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Beam Therapeutics Inc
BEAM
19
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Beam Therapeutics Inc's expected revenue for the next quarter?
Beam Therapeutics Inc's expected revenue is 15.30M.
What is Beam Therapeutics Inc's price target?
Analysts forecast that Beam Therapeutics Inc's price target is USD 42.00, with the highest forecast at USD 80.00 and the lowest forecast at USD 21.00.
How have Beam Therapeutics IncBEAM's recent earnings per share performed?
The market expectation was USD -0.91, while Beam Therapeutics IncBEAM's earnings per share (EPS) for the previous quarter was USD 2.37. EPS for the next quarter is expected at USD -1.12.
What is the analyst rating for Beam Therapeutics Inc?
Based on the ratings of Beam Therapeutics Inc's stock from 19 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
